CHI is presenting a series of blog articles on the speakers who will be addressing families attending the Fourth Congenital Hyperinsulinism Family Conference March 17 and 18, 2012, in Philadelphia, PA. In this article, we present Dr. Pascale de Lonlay.
Dr. Pascale de Lonlay is now a veteran of the Congenital Hyperinsulinism Family Conferences. I first met her in 2006 at our second Philadelphia conference. She is a wonderful speaker, very compassionate and articulate, and she is a preeminent pediatric endocrinologist.
Dr. de Lonlay is responsible for some of the major advances in in the understanding of congenital hyperinsulinism. She and her associates at the Necker-Enfants Malades Hospital (a leading children’s hospital in Paris) have done excellent work identifying babies with focal lesions. They have found that about half of the patients who require surgery have potentially curable focal lesions.
Dr. de Lonlay has been a leader in developing a team approach to the diagnosis and treatment of these infants, using interventional radiologic procedures and intra-operative histology, to identify and cure those with focal disease.
Dr. de Lonlay, along with her colleagues, has also successfully treated patients with long-acting octreotide. She will speak at the conference about how this long-acting octreotide has improved the quality of life for many of her patients.
